OptimizeRx (OPRX)
Connects life-sciences marketers, clinicians, and patients through prescribing, engagement, and consumer-audience tools.
Something off on this page? Send us feedback.
Offers digital tools that connect life-sciences marketers with health-care professionals and patients through EHR and e-prescribing workflows. The business has expanded from co-pay messaging into patient engagement, specialty prescribing, and privacy-oriented consumer audience activation.
Connects life-sciences companies, health-care professionals, and patients through workflow-embedded communications. Its original service placed coupon and co-pay assistance messages inside EHR and e-prescribing systems. CareSpeak added direct patient interactive health messaging, while EvinceMed added a platform for specialty-pharmaceutical transactions among manufacturers, hub providers, and pharmacies.
Consumer-audience capabilities added through Medicx pair omnichannel marketing and analytics with a health-care-professional-oriented platform. Current materials describe the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT), which uses privacy-safe, geography-based targeting rather than identified patients. The business is rooted in health-care workflows and patient communications.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | UBS | Target | Target: $10 | Target: $11 |
| Aug 13, 2026 | Stifel Nicolaus | Target | Target: $14 | Target: $12 |
| May 13, 2026 | UBS | Target | Target: $23 | Target: $10 |
| May 13, 2026 | Lake Street | Reiterate | Rating: —Target: — | Target: $11 |
| May 13, 2026 | Stephens | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $24.1M · Total debt $19.5M · Total assets $164.3M · Shareholders' equity $131.1M
- Revenue
- $20.5M
- Operating income
- −$88.0K
- Net income
- −$703.0K
No dividends on record.
| Institutions | 59.59% | 11.22M shares | |
|---|---|---|---|
| 117 holders · as of Jun 30, 2026 | |||
| Insiders | 23.35% | 4.40M shares | |
| 16 holders · as of Sep 2, 2026 | |||
| Strategic holders | 18.08% | 3.41M shares | |
| 2 holders · as of Jan 27, 2022 | |||
| Adds to | 101.02% | ||
18.84M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 101.02%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Strategic | 14.16% | 2.67M | filed Jan 27, 2022 |
Whetstone Capital Advisors, LLCInstitution | 8.01% | 1.51M | as of Jun 30, 2026 |
Michael WeintraubInsider | 7.35% | 1.38M | filed Nov 28, 2023 |
Royce & Associates LPInstitution | 5.78% | 1.09M | as of Jun 30, 2026 |
Harvey L. PoppelInsider | 4.05% | 762,660 | filed Mar 17, 2021 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 19, 2025 | Edward Stelmakh | officer: Chief Finance & Strat Officer | −1,388 | $13.51 |
| Oct 3, 2025 | Stephen L. Silvestro | officer: Chief Executive Officer | −1,620 | $18.75 |
- IQVIA
Life-sciences commercial data, analytics, and engagement platform
- Veeva Systems
Life-sciences commercial cloud and data software
- Doximity
Digital HCP marketing and sponsored engagement for pharma
- GoodRx
Pharma affordability and consumer-access solutions
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OptimizeRx | $7.62 | −0.39% | $141.9M | 32.4 | 8.5 | 1.4 | −29.8% |
| IQVIA | $270.09 | +0.01% | $44.42B | 33.5 | 19.9 | 2.6 | +8.7% |
| Veeva Systems | $260.91 | −0.03% | $42.45B | 43.0 | 27.1 | 12.3 | +17.6% |
| Doximity | $26.51 | +0.04% | $5.02B | 31.6 | 18.9 | 7.7 | +7.3% |
| GoodRx | $3.57 | +3.57% | $1.18B | 79.8 | 10.2 | 1.5 | −1.3% |
| Median | 38.2 | 19.4 | 5.1 | +8.0% |